Epiphany Biosciences, Inc.

Epiphany Biosciences, Inc.

Epiphany Biosciences, Inc.

Overview
Date Founded

2006

Headquarters

1 California Street,Suite 2800,San Francisco, CA 94111

Type of Company

Private

Employees (Worldwide)

1 - 10

Industries

Medical Products & Equipment
IT Consulting & Services
Pharmaceuticals
Medical Support Services
Biotechnology
Hospitals & Patient Services
Holding Companies

Company Description

Epiphany Biosciences, Inc. develops therapeutic products and diagnostic technologies that treat and prevent the spread of pathogenic viruses. The firm develops therapeutics to prevent spread of varicella zoster virus (VZV), Epstein-Barr virus (EBV), and hepatitis C virus (HCV). The company was founded by David C Myles, Robert Charles Gallo, Harold E Selick and Frederick Volinsky in 2001 and is headquartered in San Francisco, CA.

Executives & Employees

Chairman & Chief Executive Officer

Senior Advisor

Chief Medical Consultant & Director

Product Management Team

Board of Directors

Chairman & Chief Executive Officer at Epiphany Biosciences, Inc.

Paths to Epiphany Biosciences, Inc.
Potential Connections via
Relationship Science
You
Epiphany Biosciences, Inc.
Investors
Details Hidden

Wexford Capital LP is a hedge fund manager located in Greenwich, Connecticut. The firm was formed in February 2009 and is the successor to Wexford Capital LLC, formed in December 1995, and Wexford Management Corp., which was originally incorporated in May 1994. The firm serves as investment adviser, sub-adviser, manager or general partner with discretionary trading authority to private pooled investment vehicles, including U.S. limited partnerships and limited liability companies and non-U.S. corporations structured as hedge funds and private equity funds.

Details Hidden

CDIB BioScience Venture Management targets mid- to late-stage, North American, European and Taiwanese life science and healthcare companies. Early stage investments are also is considered on a case-by-case basis. They are particularly interested in the fields of drug discovery, drug development, platform technologies, medical diagnostics, biopharmaceuticals, drug delivery and medical devices. Investments range from $2 million to $5 million. CDIB participates in private financings (including preferred stock, common stock and warrants/options) and in joint ventures and corporate partnerships.

Details Hidden

Medivir AB engages in the development of pharmaceuticals products. The firm focuses on the discovery and development of transformative active cancer drugs. Its portfolio includes proprietary pipeline such as remetinostat, birinapant, MV-818, MV-828, and MIV-711 projects; and partnership pipeline which covers xerclear and MIV-802 project. The company was founded in 1988 and is headquartered in Huddinge, Sweden.

This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Epiphany Biosciences, Inc.. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Epiphany Biosciences, Inc.'s profile does not indicate a business or promotional relationship of any kind between RelSci and Epiphany Biosciences, Inc..